Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease

Table 2 CMR variables

	Appropriate device therapy (n = 14)	No appropriate device therapy (n = 52)	p value
CMR-ICD delay, months	1.6 ± 1.9	3.9 ± 6.5	0.20
CMR haemodynamic data
LVEF, %	20.8 ± 9	24.1 ± 8	0.076
LV EDV, ml	275 ± 74	245 ± 50	0.073
LV ESV, ml	214 ± 47	196 ± 42	0.16
LV mass, g	205 ± 63	183 ± 36	0.09
CMR-LGE
Percent scar, %	15.1 ± 8.2	9.9 ± 5.6	0.026
Scar Mass, g	29.6 ± 14.5	17.1 ± 8.8	< 0.005
Transmural scar extent
STAB method
Total, n	11.7 ± 3.8	10.4 ± 3.1	0.20
≤24%, n	5.6 ± 2.4	6.1 ± 2.4	0.45
25-49%, n	2.6 ± 1.7	2.3 ± 1.7	0.55
50-74%, n	2.0 ± 1.3	1.3 ± 1.3	0.09
≥75%, n	1.5 ± 1.9	0.7 ± 1.0	0.13
STLB method
Total, n	11.9 ± 3.9	10.5 ± 3.1	0.20
≤24%, n	5.7 ± 2.1	6.2 ± 2.3	0.51
25-49%, n	2.7 ± 1.7	2.3 ± 1.7	0.49
50-74%, n	2.2 ± 1.3	1.4 ± 1.2	0.031
≥75%, n	1.3 ± 1.7	0.6 ± 0.9	0.22
WIT method
Total, n	11.9 ± 3.9	10.5 ± 3.1	0.20
≤24%, n	7.9 ± 3.0	7.7 ± 2.4	0.99
25-49%, n	2.6 ± 2.1	2.1 ± 1.7	0.51
50-74%, n	1.3 ± 1.9	0.6 ± 0.8	0.53
≥75%, n	0.1 ± 0.3	0.1 ± 0.3	0.95
SMST method
Total, n	12.4 ± 3.4	10.6 ± 3.1	0.062
≤24%, n	0.6 ± 0.8	0.7 ± 0.8	0.61
25-49%, n	1.3 ± 1.4	1.2 ± 1.5	0.72
50-74%, n	1.4 ± 1.6	1.7 ± 1.4	0.36
≥75%, n	9.1 ± 3.3	6.9 ± 3.5	0.03

Data are expressed as mean±SD. "n" indicates the number of LV segments. LV indicates left ventricular; LV EDV, LV end-diastolic volume; LV ESV, LV end-systolic volume; LVEF, left ventricular ejection fraction; LV mass, left ventricular mass; CMR-LGE, late gadolinium enhancement cardiac magnetic; STAB, scar transmurality area based; STLB, scar transmurality line based; WIT, weighed infarct transmurality; SMST, spatial maximal transmurality.

ISSN: 1532-429X